DNM1L and lung adenocarcinoma: DNM1L was associated with poor survival in lung adenocarcinoma patients when co-expressing with PKP3[20], and nuclear expression of DNM1L was correlated with not only poor prognosis for lung adenocarcinoma but also drug resistance during hypoxia [29].